mustang
bio
participate
three
september
virtual
investor
conferences
worcester
globe
newswire
mustang
bio
mustang
nasdaq
mbio
biopharmaceutical
company
focused
translating
today
medical
breakthroughs
cell
gene
therapies
potential
cures
hematologic
cancers
solid
tumors
rare
genetic
diseases
today
announced
manuel
litchman
president
chief
executive
officer
participate
three
virtual
investor
conferences
september
company
also
host
virtual
meetings
conferences
details
events
follows
wainwright
nd
annual
global
investment
conference
presentation
monday
september
edt
annual
global
investment
conference
presentation
monday
september
edt
cantor
virtual
global
healthcare
conference
fireside
chat
wednesday
september
edt
oppenheimer
fall
healthcare
life
sciences
medtech
summit
fireside
chat
monday
september
edt
live
webcasts
presentation
fireside
chats
available
events
page
investors
relations
section
mustang
website
archived
replays
webcasts
available
approximately
days
following
presentation
fireside
chat
mustang
bio
mustang
bio
biopharmaceutical
company
focused
translating
today
medical
breakthroughs
cell
gene
therapies
potential
cures
hematologic
cancers
solid
tumors
rare
genetic
diseases
mustang
aims
acquire
rights
technologies
licensing
otherwise
acquiring
ownership
interest
fund
research
development
outlicense
bring
technologies
market
mustang
partnered
top
medical
institutions
advance
development
car
therapies
across
multiple
cancers
well
lentiviral
gene
therapy
xscid
mustang
registered
securities
exchange
act
amended
files
periodic
reports
securities
exchange
commission
sec
mustang
founded
fortress
biotech
nasdaq
fbio
information
visit
statements
press
release
may
contain
statements
within
meaning
section
securities
act
section
securities
exchange
act
amended
statements
include
limited
statements
relating
growth
strategy
product
development
programs
statements
historical
facts
statements
based
management
current
expectations
subject
risks
uncertainties
could
negatively
affect
business
operating
results
financial
condition
stock
value
factors
could
cause
actual
results
differ
materially
currently
anticipated
include
risks
relating
growth
strategy
ability
obtain
perform
maintain
financing
strategic
agreements
relationships
risks
relating
results
research
development
activities
risks
relating
timing
starting
completing
clinical
trials
uncertainties
relating
preclinical
clinical
testing
dependence
suppliers
ability
attract
integrate
retain
key
personnel
early
stage
products
development
need
substantial
additional
funds
government
regulation
patent
intellectual
property
matters
competition
well
risks
described
sec
filings
expressly
disclaim
obligation
undertaking
release
publicly
updates
revisions
statements
contained
herein
reflect
change
expectations
changes
events
conditions
circumstances
statement
based
except
required
law
company
contacts
jaclyn
jaffe
william
begien
mustang
bio
ir
investor
relations
contact
daniel
ferry
lifesci
advisors
llc
daniel
